Literature DB >> 15596575

Association between the CYP3A5 genotype and blood pressure.

Herbert Ho1, Amar Pinto, Stephen D Hall, David A Flockhart, Lang Li, Todd C Skaar, Peter Cadman, Daniel T O'Connor, Urban Wagner, Naomi S Fineberg, Myron H Weinberger.   

Abstract

We tested the hypothesis that the presence of a CYP3A5*1 allele is associated with increases in blood pressure in 2 studies of subjects with a total of 683 participants. The first study involving 271 subjects was part of a longitudinal study conducted at Indiana University Medical Center that consisted of 2 phases. The first phase studied the relationship of salt sensitivity with blood pressure, whereas the second phase, conducted approximately 26 years later, studied the relationship between blood pressure, carbohydrate intolerance, and vascular compliance in the same subjects. The second study was a cross-sectional evaluation of 412 normotensive and hypertensive subjects conducted at the University of California San Diego. The second study (Mantel-Haenszel chi(2) test; P=0.05) showed that a greater proportion of black participants with poor blood pressure control had CYP3A5*1/*1 genotype. Evaluation of the untreated blood pressure from phase 1 of the first study showed that the blacks with CYP3A5*3/*3 (146+/-35 mm Hg) had a higher systolic blood pressure than those with the *1/*3 (119+/-14.1 mm Hg; P=0.0006) and *1/*1 (125+/-17.4 mm Hg; P=0.009) genotypes. For blacks in study 2, the CYP3A5*1 allele was more common in hypertensives (Fisher exact test; P=0.025) than normotensives. In whites there was no association between CYP3A5 genotype and blood pressure in either study. We conclude that although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15596575     DOI: 10.1161/01.HYP.0000151361.31736.96

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  25 in total

Review 1.  Proximal tubular function and salt sensitivity.

Authors:  Michel Burnier; Murielle Bochud; Marc Maillard
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 2.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.

Authors:  Lang Li; Menggang Yu; Robarge D Jason; Changyu Shen; Faouzi Azzouz; Howard L McLeod; Silvana Borges-Gonzales; Anne Nguyen; Todd Skaar; Zeruesenay Desta; Christopher J Sweeney; David A Flockhart
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

Review 4.  Genetic architecture of complex traits predisposing to nephropathy: hypertension.

Authors:  Steven C Hunt
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

Review 5.  Natriuretic Peptides as a Novel Target in Resistant Hypertension.

Authors:  Pratik Patel; Horng H Chen
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

Review 6.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

7.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

8.  Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Authors:  Antonius E van Herwaarden; Els Wagenaar; Cornelia M M van der Kruijssen; Robert A B van Waterschoot; Johan W Smit; Ji-Ying Song; Martin A van der Valk; Olaf van Tellingen; José W A van der Hoorn; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 9.  CYP3A5 polymorphism, amlodipine and hypertension.

Authors:  Y-P Zhang; X-C Zuo; Z-J Huang; J-J Cai; J Wen; D D Duan; H Yuan
Journal:  J Hum Hypertens       Date:  2013-07-18       Impact factor: 3.012

10.  Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study.

Authors:  Ignacio Cruz-González; Esther Corral; María Sánchez-Ledesma; Angel Sánchez-Rodríguez; Cándido Martín-Luengo; Rogelio González-Sarmiento
Journal:  BMC Cardiovasc Disord       Date:  2009-08-04       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.